SITC 2025

SITC 2025 brings together leaders in immuno-oncology to explore cutting-edge science in cancer immunotherapy. At this year’s event, Nordic Bioscience will join the discussion around biomarker strategies for the tumor microenvironment, with a particular focus on tumor fibrosis.

A central part of our contribution is the nordicPRO-C3™ biomarker, which captures active remodeling of type III collagen—a key feature of cancer-associated fibroblast (CAF) activity. Recognized with a Letter of Support from the FDA, nordicPRO-C3™ is gaining traction as a non-invasive biomarker to monitor tumor fibrosis, immune exclusion, and treatment response across a range of solid tumors.

We look forward to connecting with the immuno-oncology community at SITC to help advance precision approaches in cancer therapy.